It is these foundational papers, that eventually attracted others to this field of immunoregulation by extracellular nucleotides, led to the novel principle of INHIBITION of adenosine-A2A for immunoenhancement in cancer therapies , created an "anti-A2-adenosinergic" industry and targeting of A2AR/A2BR and CD39/CD73.
Response:
We thank the Reviewer for his constructive criticisms which undoubtedly has raised the quality of our review. As recommended, our review now begins with the following statement: "The development of adenosine-targeting agents stems from foundational insights from a large body of biochemical, immunological, genetic and pharmacological studies demonstrating the broad immunosuppressive effects of extracellular adenosine (Nature. 2001 Dec 20-27; 414(6866):916-20; Huang, Blood 90:1600 -1610 Wolberg G, 1975, Science) . Notably, using mice genetically deficient in adenosine A2A receptor, Sitkovsky and colleagues provided the first genetic evidence of the critical importance of the adenosinergic pathway in tumor immunity (Ohta, PNAS, 2006) ". Suggestion #2: Authors may then illuminate the Reader by explaining that the first genetic and pharmacological evidence that extracellular adenosine is A) immunosuppressive in vivo and B) is important in regulation of immune response in vivo could NOT be obtained without focus on deletion of A2AR gene as was done by Ohta et al. This is because it was impossible to have genetic "knock-out" of extracellular adenosine or genetic "knock-out" of intracellular cAMP due to myriad of their needed for cell survival cellular functions.
As recommended, our review now begins with the following statement: "The development of adenosine-targeting agents stems from foundational insights from a large body of biochemical, immunological, genetic and pharmacological studies demonstrating the broad immunosuppressive effects of extracellular adenosine (Nature. 2001 Dec 20-27; 414(6866):916-20; Huang, Blood 90:1600 -1610 Wolberg G, 1975, Science) . Notably, using mice genetically deficient in adenosine A2A receptor, Sitkovsky and colleagues provided the first genetic evidence of the critical importance of the adenosinergic pathway in tumor immunity (Ohta, PNAS, 2006) ". Suggestion #3: Authors should explain to the Reader that the power of the immunosuppression by extracellular adenosine-A2R-cAMP events not only because it leads to the direct inhibition of TCR-activation of T cells , but also -in addition: the Adenosine -A2R-cAMP leads to immunosuppressive transcription in surrounding cells due to the phosphorylation by PKA of cAMP element binding protein (CREB) as first proposed by SitkovskyMV. T regulatory cells: hypoxiaadenosinergic suppression and re-direction of the immune response.. Trends Immunol. 2009 Mar;30(3):10
Response: We agree with the Reviewer's suggestion that the Rationale to studies of CD39/CD73 is due to the solid understanding of the molecular mechanism of extracellular nucleotides-mediated immunosuppression. The following sentence was thus added to our manuscript:
"Adenosine-mediated immunosuppression has been extensively reviewed elsewhere (PMID: 31201720). High affinity A2A and low affinity A2B adenosine receptors induce cyclic AMP response element (CRE) dependent redirection of transcription in T cells and myeloid cells (PMID: 19201652)".
Suggestion #4:
Discussing CD39 as the target for inhibition in order to improve anti-tumor immune response cannot be limited only to anti-CD39 mAb or inhibitors. Reader should be also explained the implications of connection of Hypoxia-HIF-1alpha (-Upstream-) with CD39/CD73-Ado-A2AR-cAMP (-downstream-). Suggestion #5: Authors also should also explain the therapeutic promise of using oxygen and oxygenation agents as treatments to inhibit the CD39 expression and CD73 expression and CD39/CD73-mediated generation of extracellular adenosine.
"Oxygen and oxygenation agents, alone or in combination with CD39 or CD73 inhibitors, to further decrease tumor adenosine levels also constitutes another potential strategy (PMID: 25739764)".
Suggestion #7:
Discussing prospects of therapeutic targeting CD39/CD73 Authors should inform the Reader why the targeting of individual adenosine-generating enzymes is fraught with problem of redundancies. -CD38? -Alkaline phosphatase?+++? Authors should offer their opinion IF the targeting of apyrases like CD39 and adenosine generating enzymes or CD73 has clinical promise in view of redundancy of these enzymes and comment on work on adenosine-generating CD38 and NK cells of Fabio Malavasi in JI that provided evidence for the redirection of NK toward immunosuppressive phenotype as was predicted in Sitkovsky's 2009 Trends Immunology Response: We agree that redundancies in adenosine-generating enzymes might constitute an important limiting factor to CD39-and CD73-targeting therapies. We added the following sentence to our concluding remarks: "Finally, it remains unclear whether targeting of individual adenosine-generating enzymes may be limited with potential redundancies. For instance, the ectoenzyme CD38 can generate AMP from NAD+ and has been shown to participate in tumor immune escape (PMID: 30012853). Similarly, tissue-specific and nonspecific alkalines phosphates may provide a source of extracellular adenosine independently of CD73."
Reviewer #2:
Comment 1) The first two paragraphs discuss the same activity of CD39 from the ATP and Adenosine point of view. I suggest that the authors combine both paragraphs and use the first "CD39 and ATP signaling" to introduce ATP function (I would also suggest to modify the title in this sense) and, in the second paragraph, detail CD39 activity by converting ATP into Adenosine and the associated immune suppression. Otherwise the first paragraph feels truncated since CD39 activity is not described until the second paragraph "CD39 and adenosine signaling".
